A novel antibody that has shown it can delay the onset of Type 1 diabetes received a positive opinion from the European Medicines Agency on 14 November. Teizeild (teplizumab) has been developed for the most advanced stage of disease onset when most pancreatic beta cells have been destroyed, insulin production is down, and blood sugar levels are rising. The same product, known as Tzield, was approved by the US Food and Drug Administration in 2022.
